-
NETosis-associated serum biomarkers are reduced in type 1 diabetes in association with neutrophil count.
Clin Exp ImmunolQin J, Fu S, Speake C, Greenbaum CJ, Odegard JM -
The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.
DiabetologiaMeah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C, Type 1 Diabetes TrialNet Study Group. -
HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.
DiabetesPugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum CJ, Eisenbarth GS, Sosenko JM, Type 1 Diabetes TrialNet Study Group. -
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Eur J ImmunolCabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ, Type 1 Diabetes TrialNet Canakinumab Study Group., Mandrup-Poulsen T, AIDA Study Group., Hessner MJ -
Identification of tissue-specific cell death using methylation patterns of circulating DNA.
Proc Natl Acad Sci U S ALehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y -
Acute hyperglycemia impairs IL-6 expression in humans.
Immun Inflamm DisSpindler MP, Ho AM, Tridgell D, McCulloch-Olson M, Gersuk V, Ni C, Greenbaum CJ, Sanda S -
Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.
Diabetes CareWherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Diabetes CareInsel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG -
Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.
J Diabetes Sci TechnolMauseth R, Lord SM, Hirsch IB, Kircher RC, Matheson DP, Greenbaum CJ -
Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.
Diabetes Metab Res RevBollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ, Type 1 Diabetes TrialNet Study Group. -
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin InvestRigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR -
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Pharmacol ResLord S, Greenbaum CJ -
The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.
Diabetes CareHao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP -
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Diabetes CareSosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. -
Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.
Diabetes CareDavis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, Peters AL, Beck RW, Greenbaum CJ, T1D Exchange Clinic Network.
